<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Galzus Research on Finance Insights Daily</title><link>https://finance.dpfeed.com/tags/galzus-research/</link><description>Recent content in Galzus Research on Finance Insights Daily</description><image><title>Finance Insights Daily</title><url>https://finance.dpfeed.com/images/finance-insights-og.jpg</url><link>https://finance.dpfeed.com/images/finance-insights-og.jpg</link></image><generator>Hugo -- 0.147.7</generator><language>en-us</language><lastBuildDate>Wed, 08 Oct 2025 05:32:39 +0000</lastBuildDate><atom:link href="https://finance.dpfeed.com/tags/galzus-research/index.xml" rel="self" type="application/rss+xml"/><item><title>Verastem's Downgrade: Can Development &amp; Commercialization Recover?</title><link>https://finance.dpfeed.com/posts/verastem-s-downgrade-can-development-commercialization-recover/</link><pubDate>Wed, 08 Oct 2025 05:32:39 +0000</pubDate><guid>https://finance.dpfeed.com/posts/verastem-s-downgrade-can-development-commercialization-recover/</guid><description>Financial analysis and investment insights on Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) for smart investors.</description></item></channel></rss>